Bangalore, March 18, 2009
Biocon, Indian biotechnology major announced that it had been honoured as the Best Listed Company 2009 by BioSingapore in the biotechnology field in Asia Pacific. The 2009 BioSingapore Asia Pacific Biotechnology Awards were given out at the BioSingapore Awards Gala Dinner held during BioMedical Asia 2009 at Singapore on Tuesday 17 March. These awards are a prestigious accolade for the winners from their peers, for accomplishments in the Life Sciences industry, and for the significant contributions they have made in advancing the sector in the Asia-Pacific region. This is the second year that BioSingapore has recognised biotech leaders from Asia-Pacific through its awards.
Biocon was adjudged the best listed company based on significant market capital, sound business model and excellent management team.
“To be felicitated by peers in the Biotechnology sphere in the Asia Pacific region is a great honour. We have always believed at Biocon that the difference lies in our DNA and striving towards affordable innovation is our mantra. We are delighted to be recognized for our achievements by BioSingapore” remarked Kiran Mazumdar Shaw, CMD Biocon
Every year, BioSingapore receives nominations from biotechnology industry associations (BNAP), industry peers, academics and institutions across Asia- Pacific for the most outstanding companies or individuals in various categories. The nominees are judged by a panel of distinguished leaders in the field.
BioSingapore was established in May 2004 as the industry association for life sciences and biotechnology businesses based in Singapore. With members from across the sector, BioSingapore’s goal is to “Create, Develop, and promote” the burgeoning biomedical sciences cluster in Singapore and throughout the region. BioSingapore’s members have operations and business linkages across Asia-Pacific, and the organization is an active member of BioNet Asia Pacific (BNAP) network of national biotechnology industry associations.
Established in 1978, Biocon Limited is recognized as India's premier biotechnology company. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance.
Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™ in September, 2006.